1Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER): a Randomised Controlled Trial[J]. Lancet(S0140- 6736), 2002, 360(9346) : 1623- 1630.
2Albert MA, Danielson E, Rifai N, et al. Effect of Statin Therapy on C-reactive Protein Levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE) : a Randomized Trial and Cohort Study[J]. JAMA(S0098-7484) ,2001,286(1) :64-70.
3Gotto Jr AM Jr, Farmer JA. Pleiotropic Effects of Statins: do They Matter[J]? Curr Opin Lipidol (S0957 - 9672), 2001,12 (4) :391-394.
4Almuti K, Rimawi R, Spevaek D, et al. Effects of Statins Beyond Lipid Lowering: Potentialfor Clinical Benefits[J]. Int J Cardiol(S0167- 5273) ,2006,109(1) :7- 15.
5Mercuro G,Zoncu S,Saiu F,et al.Effect of atorvastatin on endothelium-dependent vasodilation in postmenopausal women with average serum cholesterol levels[J].Am J Cardiol,2002,90(7):747-750.
6Newman CB,Palmer G,Silbershatz H,et al.Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients[J].Am J Cardiol,2003,92(6):670-676.
7Erbs S,Beck EB,Linke A,et al.High-dose rosuvastatin in chronic heart failure promotes vasculogenesis,corrects endothelial function,and improves cardiac remodeling--Results from a randomized,double-blind,and placebo-controlled study[J].Int J Cardiol,2010.
8Olsson AG,Pears J,McKellar J,et al.Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia[J].Am J Cradiol,2001,88(5):504-508.
9Maroo BP,Lavie CJ,Milani RV.Efficacy and safety of intensive statin therapy in the elderly[J].Am J Geriatr Cardiol,2008,17(2):92-100.
10Newman C,Tsai J,Szarek M,et al.Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients[J].Am J Cardiol,2006,97(1):61-67.
